NKT cell immune responses to viral infection

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 2, 2009, Pages 153-162

  Tessmer, Marlowe S ^a   Fatima, Ayesha ^a   Paget, Christophe ^b   Trottein, Francois ^b   Brossay, Laurent ^a  

^a BROWN UNIVERSITY   (United States)

^b INSERM   (France)

Author keywords

Immune response; Invariant NKT cells; Viruses

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CERAMIDE DERIVATIVE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; ISOGLOBOTRIHEXOSYLCERAMIDE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; ANTIGEN; CYTOKINE; GLYCOLIPID;

ALPHAPROTEOBACTERIA; BACTERIAL INFECTION; BACTERIUM; BORRELIA BURGDORFERI; BORRELIA INFECTION; CELL ACTIVATION; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; EHRLICHIA; ENCEPHALOMYOCARDITIC VIRUS; HERPES SIMPLEX VIRUS; HOST RESISTANCE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MURINE ENCEPHALOMYELITIS VIRUS; NATURAL KILLER T CELL; NONHUMAN; PARASITE; PATHOGENESIS; PICORNAVIRUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RICKETTSIA; SALMONELLA; SALMONELLOSIS; SPHINGOMONAS; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS; VIRUS; VIRUS INFECTION; ANIMAL; DRUG DELIVERY SYSTEM; IMMUNOLOGY; NATURAL KILLER CELL;

ANIMALS; ANTIGENS; ANTIGENS, CD1D; CYTOKINES; DRUG DELIVERY SYSTEMS; GLYCOLIPIDS; HUMANS; KILLER CELLS, NATURAL; VIRUS DISEASES;

EID: 64349106545     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802653601     Document Type: Review

References (105)

1. Brigl M, Brenner MB. CD1: Antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-890 (Pubitemid 38680443)
2. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2004;23:877-900
3. Godfrey DI, MacDonald HR, Kronenberg M, et al. NKT cells: what's in a name? Nat Rev Immunol 2004;4(3):231-237
4. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2006;25:297-336 (Pubitemid 46697911)
5. Matsuda JL, Gapin L. Developmental program of mouse Va14i NKT cells. Curr Opin Immunol 2005;17(2):122-130 (Pubitemid 40343097)
6. Rymarchyk SL, Lowenstein H, Mayette J, et al. Widespread natural variation in murine natural killer T-cell number and function. Immunology 2008. Published online 26 April 2008, doi:10.1111/j.1365-2567.2008.02846
7. Motsinger A, Haas DW, Stanic AK, et al. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 2002;195(7):869-879 (Pubitemid 34286758)
8. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human Vα24 natural killer T cells. J Exp Med 2002;195(5):637-641 (Pubitemid 34461508)
9. Couedel C, Peyrat MA, Brossay L, et al. Diverse CD1d-restricted reactivity patterns of human T cells bearing 'invariant' AV24BV11 TCR. Eur J Immunol 1998 ; 28 (12): 4391-4397 (Pubitemid 28558670)
10. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195(5):625-636 (Pubitemid 34461507)
11. Takahashi T, Nieda M, Koezuka Y, et al. Analysis of human V α 24+ CD4+ NKT cells activated by α-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000;164(9):4458-4464 (Pubitemid 30238040)
12. Metelitsa LS, Naidenko OV, Kant A, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001;167(6):3114-3122 (Pubitemid 32852549)
13. Kawano T, Nakayama T, Kamada N, et al. Antitumor cytotoxicity mediated by ligand-activated human V α 24 NKT cells. Cancer Res 1999;59(20):5102-5105 (Pubitemid 29503967)
14. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science 1997;278(5343):1626- 1629 (Pubitemid 27516282)
15. Kobayashi E, Motoki K, Uchida T, et al. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995;7(10-11):529-534 (Pubitemid 26077987)
16. Carnaud C, Lee D, Donnars O, et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163(9):4647-4650 (Pubitemid 29501223)
17. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000;30(4):985-992 (Pubitemid 30216213)
18. Burdin N, Brossay L, Kronenberg M. Immunization with a-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999;29(6):2014-2025 (Pubitemid 29265558)
19. Hermans IF, Silk JD, Gileadi U, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003;171(10):5140-5147 (Pubitemid 37432797)
20. Fujii S, Shimizu K, Smith C, et al. Activation of natural killer T cells by a-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003;198(2):267-279 (Pubitemid 36987852)
21. Galli G, Nuti S, Tavarini S, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 2003;197(8):1051-1057 (Pubitemid 36523203)
22. Wesley JD, Robbins SH, Sidobre S, et al. Cutting edge: IFN-γ signaling to macrophages is required for optimal Vα14i NK T/NK cell cross-talk. J Immunol 2005;174(7):3864-3868 (Pubitemid 40395958)
23. Zhou D, Mattner J, Cantu C, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306(5702):1786-1789 (Pubitemid 39601398)
24. Li Y, Teneberg S, Thapa P, et al. Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry. Glycobiology 2008;18(2):158-165 (Pubitemid 351168254)
25. Speak AO, Salio M, Neville DC, et al. From the cover: Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci USA 2007;104(14):5971-5976 (Pubitemid 47175643)
26. Porubsky S, Speak AO, Luckow B, et al. From the cover: Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 2007;104(14):5977-5982 (Pubitemid 47175644)
27. Christiansen D, Milland J, Mouhtouris E, et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol 2008;6(7):e172. Published online 15 July 2008, doi:10.1371/journal. pbio.0060172
28. Wu D, Xing GW, Poles MA, et al. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 2005;102(5):1351-1356 (Pubitemid 40209173)
29. Zajonc DM, Cantu C 3rd Mattner, et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 2005;6(8):810-818
30. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 2005;35(6):1692-1701 (Pubitemid 40862317)
31. Kinjo Y, Tupin E, Wu D, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 2006 ; 7 (9): 978-986 (Pubitemid 44263912)
32. Kinjo Y, Wu D, Kim G, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434(7032):520-525 (Pubitemid 40477061)
33. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005 ; 434 (7032): 525-529 (Pubitemid 40477062)
34. Kumar H, Belperron A, Barthold SW, Bockenstedt LK. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi. J Immunol 2000 ; 165 (9): 4797-4801 (Pubitemid 30809401)
35. Brigl M, Bry L, Kent SC, et al. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003 ; 4 (12): 1230-1237 (Pubitemid 37540692)
36. Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 2007 ; 178 (5): 2706-2713 (Pubitemid 46335652)
37. Nieuwenhuis EE, Matsumoto T, Exley M, et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002 ; 8 (6): 588-593 (Pubitemid 34633436)
38. Szalay G, Ladel CH, Blum C, et al. Cutting edge: anti-CD1 monoclonal antibody treatment reverses the production patterns of TGF-β2 and Th1 cytokines and ameliorates listeriosis in mice. J Immunol 1999 ; 162 (12): 6955-6958 (Pubitemid 29277657)
39. Arrunategui-Correa V, Lenz L, Kim HS. CD1d-independent regulation of NKT cell migration and cytokine production upon Listeria monocytogenes infection. Cell Immunol 2004 ; 232 (1-2): 38-48 (Pubitemid 40732719)
40. Ranson T, Bregenholt S, Lehuen A, et al. Invariant Vα14+ NKT cells participate in the early response to enteric Listeria monocytogenes infection. J Immunol 2005 ; 175 (2): 1137-1144 (Pubitemid 41095000)
41. Amprey JL, Im JS, Turco SJ, et al. A subset of liver NKT cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 2004 ; 200 (7): 895-904 (Pubitemid 39362925)
42. Svensson M, Zubairi S, Maroof A, et al. Invariant NKT cells are essential for the regulation of hepatic CXCL10 gene expression during Leishmania donovani infection. Infect Immun 2005 ; 73 (11): 7541-7547 (Pubitemid 41587660)
43. Stanley AC, Zhou Y, Amante FH, et al. Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog 2008 ; 4 (2): e1000028 . Published online 29 February 2008, doi:10.1371/journal. ppat.1000028 (Pubitemid 351340698)
44. Mattner J, Donhauser N, Werner-Felmayer G, Bogdan C. NKT cells mediate organ-specific resistance against Leishmania major infection. Microbes Infect 2006;8(2):354-362 (Pubitemid 43214597)
45. Ishikawa H, Hisaeda H, Taniguchi M, et al. CD4+ V α 14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major. Int Immunol 2000 ; 12 (9): 1267-1274 (Pubitemid 30657770)
46. Duthie MS, Kahn M, White M, et al. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun 2005 ; 73 (1): 181-192 (Pubitemid 40041108)
47. Procopio DO, Almeida IC, Torrecilhas AC, et al. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. J Immunol 2002 ; 169 (7): 3926-3933
48. Faveeuw C, Mallevaey T, Trottein F. Role of natural killer T lymphocytes during helminthic infection. Parasite 2008 ; 15 (3): 384-388
49. Mallevaey T, Fontaine J, Breuilh L, et al. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis. Infect Immun 2007 ; 75 (5): 2171-2180 (Pubitemid 46744303)
50. Mallevaey T, Zanetta JP, Faveeuw C, et al. Activation of invariant NKT cells by the helminth parasite Schistosoma mansoni. J Immunol 2006 ; 176 (4): 2476-2485 (Pubitemid 43201699)
51. van der Vliet HJ, von Blomberg BM, Hazenberg MD, et al. Selective decrease in circulating Vα24+Vβ11+ NKT cells during HIV type 1 infection. J Immunol 2002 ; 168 (3): 1490-1495
52. Moore JP. Coreceptors: implications for HIV pathogenesis and therapy. Science 1997 ; 276 (5309): 51-52 (Pubitemid 27161239)
53. Cho S, Knox KS, Kohli LM, et al. Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex. Virology 2005 ; 337 (2): 242-252 (Pubitemid 40798992)
54. Chen N, Mccarthy C, Drakesmith H, et al. HIV-1 down-regulates the expression of CD1d via Nef. Eur J Immunol 2006 ; 36 (2): 278-286 (Pubitemid 43257450)
55. van der Vliet HJ, van Vonderen MG, Molling JW, et al. Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. J Immunol 2006 ; 177 (9): 5775-5778 (Pubitemid 44628789)
56. Huang Y, Chen A, Li X, et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide. Vaccine 2008 ; 26 (15): 1807-1816
57. Exley MA, Bigley NJ, Cheng O, et al. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leukoc Biol 2001 ; 69 (5): 713-718 (Pubitemid 32466408)
58. Exley MA, Bigley NJ, Cheng O, et al. Innate immune response to encephalomyocarditis virus infection mediated by CD1d. Immunology 2003 ; 110 (4): 519-526 (Pubitemid 37521883)
59. Ilyinskii PO, Wang R, Balk SP, Exley MA. CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo. J Virol 2006;80(14):7146-7158 (Pubitemid 44025211)
60. Hobbs JA, Cho S, Roberts TJ, et al. Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus. J Virol 2001 ; 75 (22): 10746-10754 (Pubitemid 33031544)
61. Roberts TJ, Lin Y, Spence PM, et al. CD1d1-dependent control of the magnitude of an acute antiviral immune response. J Immunol 2004 ; 172 (6): 3454-3461 (Pubitemid 38337925)
62. Shimamura M, Huang YY, Suda Y, et al. Positive selection of NKT cells by CD1+, CD11c+ non-lymphoid cells residing in the extrathymic organs. Eur J Immunol 1999 ; 29 (12): 3962-3970
63. Lin Y, Roberts TJ, Wang CR, et al. Long-term loss of canonical NKT cells following an acute virus infection. Eur J Immunol 2005 ; 35 (3): 879-889 (Pubitemid 40425544)
64. Youn HJ, Ko SY, Lee KA, et al. A single intranasal immunization with inactivated influenza virus and α -galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 2007 ; 25 (28): 5189-5198
65. Ko SY, Ko HJ, Chang WS, et al. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005;175(5):3309-3317 (Pubitemid 41170552)
66. Kamijuku H, Nagata Y, Jiang X, et al. Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 2008 ; 1 : 208-218 (Pubitemid 351541306)
67. Ho LP, Denney L, Luhn K, et al. Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur J Immunol 2008 ; 38 (7): 1913-1922
68. De Santo C, Salio M, Masri SH, et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 2008 ; 118 (12): 4036-4048
69. Durbin JE, Durbin RK. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol 2004 ; 17 (3): 370-380 (Pubitemid 39244759)
70. Krishnan S, Halonen M, Welliver RC. Innate immune responses in respiratory syncytial virus infections. Viral Immunol 2004 ; 17 (2): 220-233 (Pubitemid 38880423)
71. Tripp RA, Moore D, Barskey A 4th, et al. Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. J Infect Dis 2002 ; 185 (10): 1388-1394 (Pubitemid 34507959)
72. Johnson TR, Hong S, Van Kaer L, et al. NK T cells contribute to expansion of CD8+ T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 2002 ; 76 (9): 4294-4303 (Pubitemid 34309565)
73. Furlan R, Bergami A, Cantarella D, et al. Activation of invariant NKT cells by α GalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-γ . Eur J Immunol 2003 ; 33 (7): 1830-1838 (Pubitemid 37120854)
74. Jahng AW, Maricic I, Pedersen B, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001 ; 194 (12): 1789-1799 (Pubitemid 34028658)
75. Colucci F, Samson SI, Dekoter RP, et al. Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 2001 ; 97 (9): 2625-2632
76. Teige A, Teige I, Lavasani S, et al. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. J Immunol 2004 ; 172 (1): 186-194 (Pubitemid 38020471)
77. Mars LT, Laloux V, Goude K, et al. Cutting edge: V α 14-J α 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 2002 ; 168 (12): 6007-6011 (Pubitemid 34620014)
78. Tsunoda I, Tanaka T, Fujinami RS. Regulatory role of CD1d in neurotropic virus infection. J Virol 2008;82(20):10279-10289
79. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα 14-Jα 281 TCR. J Immunol 2003 ; 170 (3): 1430-1434 (Pubitemid 36139511)
80. Grubor-Bauk B, Arthur JL, Mayrhofer G. Importance of NKT cells in resistance to herpes simplex virus, fate of virus infected neurons and level of latency in mice. J Virol 2008 ; 82 (22): 11073-11083
81. Cornish AL, Keating R, Kyparissoudis K, et al. NKT cells are not critical for HSV-1 disease resolution. Immunol Cell Biol 2006 ; 84 (1): 13-19
82. Yuan W, Dasgupta A, Cresswell P. Herpes simplex virus evades natural killer T cell recognition by suppressing CD1d recycling. Nat Immunol 2006 ; 7 (8): 835-842 (Pubitemid 44084090)
83. Raftery MJ, Winau F, Kaufmann SHE, et al. CD1 antigen presentation by human dendritic cells as a target for herpes simplex virus immune evasion. J Immunol 2006 ; 177 (9): 6207-6214 (Pubitemid 44628839)
84. Sanchez DJ, Gumperz JE, Ganem D. Regulation of CD1d expression and function by a herpesvirus infection. J Clin Invest 2005 ; 115 (5): 1369-1378 (Pubitemid 40629057)
85. Lussier G. Murine cytomegalovirus (MCMV). Adv Vet Sci Comp Med 1975 ; 19 : 223-247
86. Dokun AO, Kim S, Smith HR, et al. Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2001 ; 2 (10): 951-956 (Pubitemid 32976168)
87. French AR, Sjolin H, Kim S, et al. DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections. J Immunol 2006 ; 177 (8): 4981-4990 (Pubitemid 44527567)
88. Daniels KA, Devora G, Lai WC, et al. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J Exp Med 2001 ; 194 (1): 29-44 (Pubitemid 32660435)
89. Lee SH, Girard S, Macina D, et al. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 2001 ; 28 (1): 42-45 (Pubitemid 32405814)
90. Brown MG, Dokun AO, Heusel JW, et al. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 2001 ; 292 (5518): 934-937 (Pubitemid 32422491)
91. Arase H, Mocarski ES, Campbell AE, et al. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002 ; 296 (5571): 1323-1326 (Pubitemid 34522789)
92. Voigt V, Forbes CA, Tonkin JN, et al. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci USA 2003 ; 100 (23): 13483-13488 (Pubitemid 37444768)
93. Sjolin H, Tomasello E, Mousavi-Jazi M, et al. Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J Exp Med 2002 ; 195 (7): 825-834 (Pubitemid 34286754)
94. Desrosiers MP, Kielczewska A, Loredo-Osti JC, et al. Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat Genet 2005 ; 37 (6): 593-599 (Pubitemid 40774887)
95. Andrews DM, Scalzo AA, Yokoyama WM, et al. Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol 2003 ; 4 (2): 175-181 (Pubitemid 36193020)
96. van Dommelen SL, Tabarias HA, Smyth MJ, Degli-Esposti MA. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol 2003 ; 77 (3): 1877 -1884 (Pubitemid 36110000)
97. Wesley JD, Tessmer MS, Chaukos D, Brossay L. NK cell-like behavior of V α 14i NK T cells during MCMV infection. PLoS Pathog 2008 ; 4 (7): e1000106. Published online July 18 2008, doi:10.1371/journal.ppat.1000106
98. Tyznik AJ, Tupin E, Nagarajan NA, et al. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol 2008 ; 181 (7): 4452-4456
99. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000 ; 192 (7): 921-930 (Pubitemid 30765686)
100. Ito H, Ando K, Ishikawa T, et al. Role of Vα14+ NKT cells in the development of hepatitis B virus-specific CTL: activation of Vα14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol 2008 ; 20 (7): 869-879 (Pubitemid 351865862)
101. Dong Z, Zhang J, Sun R, et al. Impairment of liver regeneration correlates with activated hepatic NKT cells in HBV transgenic mice. Hepatology 2007 ; 45 (6): 1400-1412 (Pubitemid 46918324)
102. Parekh VV, Wilson MT, Olivares-Villagomez D, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005 ; 115 (9): 2572-2583 (Pubitemid 41266220)
103. Sullivan BA, Kronenberg M. Activation or anergy: NKT cells are stunned by α-galactosylceramide. J Clin Invest 2005 ; 115 (9): 2328-2329 (Pubitemid 41266194)
104. Kim S, Lalani S, Parekh VV, Vincent TL. Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice. J Clin Invest 2008 ; 118 (6): 2301-2315 (Pubitemid 351872347)
105. Martinic MM, von Herrath MG. Novel strategies to eliminate persistent viral infections. Trends Immunol 2008 ; 29 (3): 116-124